Dr. Altschuller brings over two decades of
clinical and commercial biotechnology experience as the company
grows its clinical pipeline to five autoimmune disease and oncology
drug candidates.
WALTHAM,
Mass., Aug. 5, 2024 /PRNewswire/ -- Dragonfly
Therapeutics, Inc. today announced it has expanded its executive
leadership team with the addition of Dr. Susan Altschuller as Chief Financial
Officer.
"We are delighted that Susan has joined Dragonfly," said
Bill Haney, co-founder and CEO of
Dragonfly Therapeutics. "Her leadership growing successful
biopharma companies comes at an exciting time as Dragonfly expands
our clinical pipeline in autoimmune disease, oncology, and
neuro-inflammatory disease. Susan's powerful combination of
financial, clinical and development experience will help drive our
mission to help patients by inventing and commercializing leading
immune-engaging therapeutics."
Susan Altschuller Ph.D., MBA is a seasoned senior biopharma
executive with more than two decades of strategic and financial
leadership experience at leading pharmaceutical and biotechnology
companies. Most recently, she served as the chief financial officer
of Cerevel Therapeutics, a biotechnology company developing
therapies for neuroscience diseases, until its acquisition by
AbbVie earlier this month.
Before Cerevel, Dr. Altschuller was chief financial officer of
ImmunoGen, supporting the oncology company's first commercial
launch. Prior to ImmunoGen Dr. Altschuller worked at Alexion, where
she was vice president and head of investor relations and later,
head of enterprise finance. Dr. Altschuller has also served as head
of investor relations at Bioverativ, a hemophilia spin-off from
Biogen, and held various positions in Biogen finance and as senior
consultant at the Frankel Group. Susan received a BSE in Biomedical
Engineering with Honors from Tulane
University, a Ph.D. in Biomedical Engineering from the
Illinois Institute of Technology, and
an MBA from the MIT Sloan School of
Management. Dr. Altschuller has served as audit chair on the
Board of Directors of Vestaron Corporation and Mural Oncology and
is a founding Board member of the HNRNP Family Foundation.
About Dragonfly
Dragonfly Therapeutics is a
clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing novel therapies that harness the
body's immune system to bring breakthrough treatments to patients.
In addition to a set of advanced programs in the clinic, Dragonfly
has a deep pipeline of wholly owned preclinical candidates
discovered using its proprietary platforms that are progressing
toward the clinic, as well as productive collaborations with
AbbVie, Bristol Myers Squibb, Gilead and Merck in a broad range of
disease areas.
For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne E. Deconinck |
anne@dragonflytx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dragonfly-therapeutics-appoints-dr-susan-altschuller-as-chief-financial-officer-302213947.html
SOURCE Dragonfly Therapeutics, Inc.